Scancell signs collaboration agreement with antibody technology company

Platform to potentially increase the potency of any therapeutic monoclonal antibody

Scancell, the developer of novel immunotherapies for the treatment of cancer, is pleased to announce that it has signed its first collaboration and non-exclusive research agreement with a leading antibody technology company to assess its pipeline of monoclonal antibodies (mAbs) targeting tumourassociated glycans (TaGs) that have been enhanced with its new proprietary AvidiMab™ technology.

As previously announced over the last year, Scancell has been building its pipeline of mAbs as potential novel target cancer treatments. Most mAbs for the treatment of cancer target proteins on the cancer cell surface and subsequently mediate an immune response to eliminate that cell. However,there remains an unmet need for new and improved therapeutic targets, as well as improved approaches to mediate cell killing. All cells are covered by a dense layer of sugar structures, called glycans, which change when a normal cell turns into a cancer cell. TaGs are glycan motifs that are associated with tumour malignancies and these can be targeted by antibodies. Scancell’s development pipeline includes mAbs against specific TaGs with superior affinity and selectivity profiles, that have now been further engineered using the Company’s AvidiMab™ technology; this
confers the Scancell anti-TaG mAbs with the ability to directly kill tumour cells.

Dr Cliff Holloway, Chief Executive Officer, Scancell, commented:

“We are pleased to be able to report significant progress on our monoclonal antibody pipeline, having only licensed the technology into the company just over a year ago from the University of Nottingham. Our first collaboration and evaluation agreement with one of the major players in the antibody development field is a significant achievement in such a short period of time and we believe our novel AvidiMab™ enhanced cell killing platform has broad partnering potential.”

Read the full press release here.